Compare DLPN & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | JSPR |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 22.9M |
| IPO Year | 2008 | N/A |
| Metric | DLPN | JSPR |
|---|---|---|
| Price | $1.08 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 10.8K | ★ 2.3M |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,699,389.00 | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $0.99 | $0.32 |
| 52 Week High | $1.88 | $3.25 |
| Indicator | DLPN | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 54.24 |
| Support Level | $1.05 | $0.62 |
| Resistance Level | $1.17 | $1.05 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 40.74 | 43.37 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing, and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials. The company operates within the U.S.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.